bridge4

Woodland Research Northwest

Rogers, AR

Woodland Research Northwest Overview

Principal Investigators
Fayz Hudefi, MD
Board Certified Psychiatry

Robert Billingsley, Jr., MD
Board Certified Psychiatry and Neurology

Site Director
Nichole Gutierrez

Specialties

ADHD
Alzheimer’s Disease
Bipolar Disorder
CRPS
Depression
Essential Tremor
Migraine Headache
Opioid Use Disorder
Postpartum Depression
PTSD
QTc
Schizophrenia
Sleep Disorders
Smoking/Tobacco

Pediatric:
ADHD
Depression
Schizophrenia
Tourette’s Syndrome

Facility

  • 24-bed inpatient unit
  • Clinical pharmacology unit
  • Outpatient clinic

Special Procedures and Equipment
CSF/cCSF
Polysomnography
Smoking Room
EEG/qEEG
Crash Cart

Off-Site
MRI/fMRI
PET
X-ray
Ultrasound
DaT Scan
CT Scan

Institutional Review Board
Central

Follow Us On Social Media:
Facebook
Twitter

Contact
info@cnssites.com
+1-908-756-4411

Social Media

Did you know that without research trials, new medications will never reach the market? You can help! Woodland is currently conducting a trial related to migraine headaches. Contact us today at 479-927-3000 to find out if you are eligible to participate. Compensation and travel assistance may be available. ... See MoreSee Less

View on Facebook

News Feed

May, 2017: In July 2016, WRN re-located to a new clinical research unit. This 12,000-square-foot site with 24 beds was purpose-built for subjects participating in clinical trials. The site is equipped with PSG for sleep disorders, can conduct complex studies with serial PK draws and other special procedures. Under the direction of Dr. Fayz Hudefi, the site continues to build on its experience in psychiatry and neurology while expanding into new therapeutic areas. Over the past year, WRN has been awarded/conducted studies in opioid withdrawal, Alzheimer’s disease, essential tremors, Post-Traumatic Stress Disorder, pediatric/adolescent Tourette’s Syndrome, migraine and Complex Regional Pain Syndrome. Dr. Robert Billingsley has joined WRN with extensive experience in psychiatric indications, specifically Schizophrenia and PTSD. He will serve as a Principal Investigator and rater. WRN is planning for further expansion which  will include a dedicated indoor smoking room and a 12-bed CPU designed for special populations